LOADING
Comparing Johnson & Johnson (JNJ) and Merck & Company (MRK), both in the Health Care sector. This side-by-side analysis covers price, valuation multiples, profitability, growth, dividends, and risk metrics to help investors evaluate these two stocks.
| Metric | JNJ | MRK |
|---|---|---|
| Price | -- | -- |
| Change Today | +0.00% | +0.00% |
| Market Cap | $545.0B | $279.1B |
| P/E Ratio | 20.5 | 15.5 |
| Forward P/E | 20.0 | 22.0 |
| PEG Ratio | 3.01 | 3.44 |
| EPS | $11.04 | $7.28 |
| Revenue Growth (YoY) | 9.9% | 5.0% |
| Profit Margin | 21.8% | 28.1% |
| Return on Equity | 35.0% | 36.9% |
| Dividend Yield | 2.25% | 2.88% |
| Beta | 0.33 | 0.28 |
| 52-Week High | $251.71 | $124.22 |
| 52-Week Low | $142.16 | $70.74 |
| Volume | -- | -- |
Johnson & Johnson is the larger company by market capitalization. Merck & Company trades at a lower P/E ratio, suggesting it may offer better value relative to earnings. Merck & Company offers a higher dividend yield for income investors. Merck & Company has stronger profit margins. Both stocks should be evaluated in the context of your investment goals, risk tolerance, and portfolio diversification needs.